Stockreport

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF - Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from the first three participants show sustai [Read more]